EQ-5D in coronary patients: what are they suffering from? Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry
Coronary patients often suffer from an impaired health, hence the aim of this study is to assess how coronary patients score on the different EQ-5D dimensions.
Analyses are based on the EUROASPIRE IV survey, conducted across 24 European countries. 7567 patients with stable coronary heart disease (mean age = 64.1 (SD = 9.6); males = 75.8%) completed the EQ-5D-5L instrument, 6 months to 3 years after their index hospitalization. Descriptive statistics and multilevel logistic regression was used to assess the differences between patient groups in reported problems on the EQ-5D dimensions. Furthermore, age-standardized country-specific outcomes were reported.
About one out of four patients reported to have no problems on all five dimensions (57.9% reported no problems on mobility, 88.4% reported no problems on self-care, 67.1% reported no problems on usual activities, 41.1% reported no problems on pain/discomfort, and 56.2% reported no problems on anxiety/depression). Elderly patients and females reported more problems. Patients with behavioral risk factors and patients with comorbidities were more likely to have severe or extreme problems. Comparison across countries showed major differences in reported problems.
Whether or not coronary patients have problems on one or more EQ-5D dimension, as well as the severity of the problems reported is largely associated with the patient profile. The least problems are seen on the self-care dimension and most problems are reported on the pain/discomfort dimension.
KeywordsCoronary heart disease EQ-5D EUROASPIRE Health-related quality of life
This work was supported by AstraZeneca, Bristol Myers Squibb/Emea Sarl, GlaxoSmithKline, F Hoffman–La Roche (Gold Sponsors), Merck, Sharp & Dohme and Amgen (Bronze Sponsors) (unrestricted research Grants to the European Society of Cardiology). The EUROASPIRE IV survey was carried out under the auspices of the European Society of Cardiology, EURObservational Research Programme. The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript. The EUROASPIRE Study Group is grateful to the administrative staff, physicians, nurses and other personnel in the hospitals in which the survey was carried out and to all patients who participated in the surveys. EORP Oversight Committee, Executive Committee of the EURObservational Research Programme (EORP): Guy De Backer BE (Chair); Dirk De Bacquer, BE; Stephan Gielen, DE; Oliver Schnell, DE; Jouko Sundvall, FI; Jaakko Tuomilehto, FI; Philippe Amouyel, FR; Kornelia Kotseva, GB; David Wood, GB; Aldo P. Maggioni, IT; Lars Ryden, SE. Steering Committee: Mirza Dilic, BA; Belma Pojskic, BA; Dusko Vulic, BA; Dirk De Bacquer, BE; Johan De Sutter, BE; Nina Gotcheva, BG; Evagoras Nicolaides, CY; Jan Bruthans, CZ; Renata Cifkova, CZ; Peter Heuschmann, DE; Stefan Stoerk, DE; Almudena Castro Conde, ES; Seppo Lehto, FI; Philippe Amouyel, FR; Kornelia Kotseva, GB; David Wood, GB; Ioannis Goudevenos, GR; Davor Milicic, HR; Zeljko Reiner, HR; Bela Merkely, HU; David Moore, IE; Diego Vanuzzo, IT; Kairat Davletov, KZ; Aleksandras Laucevicius, LT; Andrejs Erglis, LV; Jaap Deckers, NL; Monika Hollander, NL; Andrzej Pajak, PL; Ana Abreu, PT; Carlos Tavares Aguiar, PT; Dan Gaita, RO; Silvia Mancas, RO; Nebojsa Lalic, RS; Dragan Lovic, RS; Rafael Oganov, RU; Nana Pogosova, RU; Viveca Gyberg, SE; Martin Stagmo, SE; Zlatko Fras, SI; Lale Tokgozoglu, TR; Maryna Dolzhenko, UA. The registry was managed and organized by the EORP department including Myriam Glemot as Project Officer, Marème Konte as Data Monitor. Overall activities were coordinated and supervised by Professor Aldo P. Maggioni (EORP Scientific Coordinator) and Thierry Ferreira (Head of EORP Department).
This work was supported by AstraZeneca, Bristol Myers Squibb/Emea Sarl, GlaxoSmithKline, F Hoffman–La Roche (Gold Sponsors), Merck, Sharp & Dohme and Amgen (Bronze Sponsors) (unrestricted research Grants to the European Society of Cardiology).
Compliance with ethical standards
Conflict of interest
None of the authors have a conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Local Research Ethics Committees approvals were obtained from each of the 74 participating centres.
Informed consent was obtained from all individual participants included in the study.
- 2.Schipper, H., Clinch, J., & Olweny, C. L. (1996). Quality of life studies: Definitions and conceptual issues. In S. B. Editor (Ed.), Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA: Lippincott-Raven.Google Scholar
- 3.WHO, Top 10 Causes of Death. Retrieved December 12, 2018, from http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
- 4.Wilkins, E., Wilson, L., Wickramasinghe, K., Bhatnagar, P., Leal, J., Luengo-Fernandez, R., et al. (2017). European cardiovascular disease statistics. Retrieved December 12, 2018, from http://www.ehnheart.org/cvd-statistics.html.
- 5.IHME. (2017). Global burden of disease. Retrieved December 12, 2018, from https://vizhub.healthdata.org/gbd-compare/.
- 6.Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., et al. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal,37(29), 2315–2381.CrossRefGoogle Scholar
- 12.EuroQol. Retrieved December 12, 2018, from https://euroqol.org/.
- 19.Kotseva, K., Wood, D., De Bacquer, D., De Backer, G., Rydén, L., Jennings, C., et al. (2016). EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology,23(6), 636–648.CrossRefGoogle Scholar
- 28.De Smedt, D., Clays, E., Höfer, S., Oldridge, N., Kotseva, K., Maggioni, A. P., et al. (2013). Health related quality of life in coronary patients and its association with their cardiovascular risk profile: Results from the EUROASPIRE III survey. International Journal of Cardiology,168(2), 898–903.CrossRefGoogle Scholar
- 30.Szende, A., & Williams, A. (2004). Measuring self-reported population health: An international perspective based on EQ-5D. Retrieved December 12, 2018, from https://euroqol.org/wp-content/uploads/2016/10/Measuring_Self-Reported_Population_Health_-_An_International_Perspective_based_on_EQ-5D.pdf.
- 34.Fortuno-Godes, J., Guerra-Balic, M., & Cabedo-Sanroma, J. (2013). Health-related quality of life measures for physically active elderly in community exercise programs in catalonia: Comparative analysis with sedentary people. Current Gerontology and Geriatrics Research,2013, 168482.CrossRefGoogle Scholar